LONDON, April 6 (Reuters) - AstraZeneca Plc faces a delay in marketing its asthma drug Symbicort to young children in the United States after regulators asked for more information, dealing a blow to ...
LONDON, June 4 (Reuters) - AstraZeneca Plc is seeking U.S. approval to market its asthma drug Symbicort as a treatment for young children, increasing the competitive pressure on GlaxoSmithKline Plc's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback